纤维化间质性肺病患者的吸入暴露:加拿大肺纤维化注册研究中的表现、肺功能与生存
该研究基于加拿大肺纤维化多中心注册队列,纳入3820例纤维化间质性肺病患者,其中2385例(62%)存在ILD相关吸入暴露。暴露与男性(调整OR 1.46,95%CI 1.28-1.68,p<0.001)和肺纤维化家族史(调整OR 1.73,95%CI 1.40-2.15,p<0.001)相关,且任何吸入暴露与移植无生存期改善相关(HR 0.81,95%CI 0.71-0.92,p=0.001),该效应在各诊断亚型中持续存在;暴露与FVC年变化的关系因ILD亚型而异。
要点
- 纤维化ILD患者中ILD相关吸入暴露报告率高达62%。
- 吸入暴露与男性及肺纤维化家族史独立相关。
- 吸入暴露与移植无生存期改善相关(HR 0.81)。
核心结论
- 纤维化ILD患者中各亚型均报告高比例的吸入暴露。
- 吸入暴露与诊断时更年轻、男性及肺纤维化家族史相关。
- 识别出吸入暴露与生存获益相关。
研究设计与样本
- 多中心加拿大肺纤维化注册队列研究,纳入3820例纤维化ILD患者。
- 通过问卷收集ILD相关职业与环境暴露信息。
- 采用线性回归、 logistic回归、线性混合效应模型及多变量Cox比例风险回归和log-rank检验分析暴露与基线年龄、性别、家族史、肺功能及生存的关系。
主要发现
- 2385例(62%)患者存在ILD相关吸入暴露。
- 暴露患者更年轻,尤其在特发性肺纤维化亚组中。
- 吸入暴露与男性相关(调整OR 1.46,95%CI 1.28-1.68,p<0.001)。
- 吸入暴露与肺纤维化家族史相关(调整OR 1.73,95%CI 1.40-2.15,p<0.001)。
- 任何吸入暴露与移植无生存期改善相关(HR 0.81,95%CI 0.71-0.92,p=0.001),且在各诊断亚型中持续存在;暴露与FVC年变化的关系因ILD亚型而异。
临床怎么用
- 在纤维化ILD患者评估中应系统采集职业与环境吸入暴露史。
- 识别吸入暴露可能有助于风险分层,但需结合亚型解读其与肺功能变化的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Inhalational exposures are a known cause of interstitial lung disease (ILD), but little is understood about their prevalence across ILD subtypes and their relationship with pulmonary function and survival. METHODS: Patients with fibrotic ILD were identified from the multicentre Canadian Registry for Pulmonary Fibrosis. Patients completed questionnaires regarding ILD-related occupational and environmental exposures. The relationship between exposures and the outcomes of baseline age, gender, family history, pulmonary function and survival was analysed using linear and logistic regression models, linear mixed-effect regression models and survival analysis using multivariable Cox proportional hazards along with the log-rank test. RESULTS: There were 3820 patients included in this study, with 2385 (62%) having ILD-related inhalational exposure. Exposed patients were younger, particularly in the idiopathic pulmonary fibrosis subgroup. Inhalational exposure was associated with male gender (adjusted OR 1.46, 95% CI 1.28-1.68, p < 0.001) and family history of pulmonary fibrosis (adjusted OR 1.73, 95% CI 1.40-2.15, p < 0.001). Patients with any inhalational exposure had improved transplant-free survival (hazard ratio 0.81, 95% CI 0.71-0.92, p = 0.001); this effect persisted across diagnostic subtypes. The relationship between exposures and annual change in forced vital capacity varied by ILD subtype. CONCLUSION: Patients with fibrotic ILD report high prevalence of inhalational exposures across ILD subtypes. These exposures were associated with younger age at diagnosis, male gender and family history of pulmonary fibrosis. Identification of an inhalational exposure was associated with a survival benefit. These findings suggest that inhaled exposures may impact clinical outcomes in patients with ILD, and future work should characterize the mechanisms underlying these relationships.
引用
- Lee CT, Strek ME, Adegunsoye A, et al. Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis. Respirology. 2022. PMID: 35512793. doi:10.1111/resp.14267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。